Stifel Maintains Buy on Dianthus Therapeutics, Raises Price Target to $65

Benzinga · 09/12/2025 14:32
Stifel analyst Alex Thompson maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Buy and raises the price target from $52 to $65.